Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985832 | 0.91 | LRRK2 (0.42) | CD274MAP4K4CCR3PDCD1LRRK2 | |
| SCHEMBL988115 | 0.88 | AXL (0.42) | PDE2ACD274PDCD1LRRK2AXL | |
| SCHEMBL986497 | 0.88 | AXL (0.42) | PDE2ACD274PDCD1LRRK2AXL | |
| SCHEMBL986495 | 0.88 | AXL (0.42) | PDE2ACD274PDCD1LRRK2AXL | |
| SCHEMBL986411 | 0.88 | LRRK2 (0.43) | CYP2D6LRRK2CNR2METAXL | |
| SCHEMBL28805617 | 0.87 | LRRK2 (0.37) | PDE2ALRRK2METLTA4HADRB2 | |
| SCHEMBL983309 | 0.86 | LRRK2 (0.43) | PDE2ACD274PDCD1LRRK2CNR2 | |
| SCHEMBL985996 | 0.86 | SPHK1 (0.44) | CD274PDCD1 | |
| SCHEMBL985994 | 0.86 | SPHK1 (0.44) | CD274PDCD1 | |
| SCHEMBL987862 | 0.84 | MAP3K9 (0.45) | MAP4K4LRRK2METAXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101479255-B | C-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2013-05-01 | — | — | CN | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | claimed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | claimed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | CYP2D6 4248/4885PDE2A 1745/4885CD274 3775/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | CYP2D6 4248/4885PDE2A 1745/4885CD274 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.